<DOC>
	<DOC>NCT02164500</DOC>
	<brief_summary>The Purpose of this trial is: - to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL - to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL</brief_summary>
	<brief_title>JAK-inhibition in Recurrent Classical Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>relapsed or refractory HL ECOG &lt;= 2, no major organ dysfunction written informed consent history of another primary malignancy â‰¤ 2 years female patients who are pregnant or breast feeding patients with a known history of HIV seropositivity chronic active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>